Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammation

被引:22
作者
Palmer, Gaby
Talabot-Ayer, Dominique
Kaya, Guerkan
Gabay, Cem
机构
[1] Univ Hosp Geneva, Div Rheumatol, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp Geneva, Sch Med, Dept Pathol & Immunol, CH-1211 Geneva 14, Switzerland
[3] Univ Hosp Geneva, Dept Dermatol, CH-1211 Geneva 14, Switzerland
关键词
D O I
10.1038/sj.jid.5700803
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The IL-1 system plays a key role in skin physiology and pathology. In this study, we used mutant mice lacking the type I IL-1 receptor (IL-1RI), lacking IL-1 receptor antagonist (IL-1Ra), or overexpressing the human intracellular (ic) IL-1Ra1 isoform, as well as combinations thereof, to dissect the role of the IL-1 system in phorbol 13myristate 12-acetate (PMA)-induced skin inflammation. In wild-type (WT) mice, PMA application induced epidermal thickening and dermal inflammation. Skin IL-1 alpha production and circulating levels of the acute-phase protein serum amyloid A (SAA) were elevated. In mice lacking IL-1RI or overexpressing icIL-1Ra1, PMA induced similar epidermal thickening as in WT mice, but dermal inflammation was partially prevented. Skin IL-1 alpha mRNA expression was similar in PMA-treated IL-1Rl-/- and WT mice, whereas the increase in serum SAA was suppressed in IL-1Rl-/- mice. Interestingly, PMA-induced IL-lar mRNA expression was further enhanced by icIL1Ra1 overexpression in an IL-1RI-dependent manner. Finally, IL-1Ra-/- mice spontaneously displayed skin lesions characterized by high IL-1 beta but not IL-1 alpha, expression. In conclusion, PMA-induced epidermal thickening and skin IL-1 alpha expression were independent of IL-1 signaling, in contrast to dermal inflammation and systemic inflammatory response.
引用
收藏
页码:1938 / 1946
页数:9
相关论文
共 38 条
[1]  
[Anonymous], [No title captured]
[2]  
ANSEL JC, 1988, J IMMUNOL, V140, P2274
[3]   Interleukin-1 receptor antagonist: Role in biology [J].
Arend, WP ;
Malyak, M ;
Guthridge, CJ ;
Gabay, C .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :27-55
[4]   Intracellular IL-1 receptor antagonist type 1 inhibits IL-1-induced cytokine production in keratinocytes through binding to the third component of the COP9 signalosome [J].
Banda, NK ;
Guthridge, C ;
Sheppard, D ;
Cairns, KS ;
Muggli, M ;
Bech-Otschir, D ;
Dubiel, W ;
Arend, WP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (06) :3608-3616
[5]   INTERLEUKIN-1 RECEPTOR ANTAGONIST PRODUCTION BY HUMAN KERATINOCYTES [J].
BIGLER, CF ;
NORRIS, DA ;
WESTON, WL ;
AREND, WP .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1992, 98 (01) :38-44
[6]   Biologic basis for interleukin-1 in disease [J].
Dinarello, CA .
BLOOD, 1996, 87 (06) :2095-2147
[7]   Action of intracellular IL-1 Ra (Type 1) is independent of the IL-1 intracellular signalling pathway [J].
Evans, I ;
Dower, SK ;
Francis, SE ;
Crossman, DC ;
Wilson, HL .
CYTOKINE, 2006, 33 (05) :274-280
[8]  
Gabay C, 2001, EUR J IMMUNOL, V31, P490, DOI 10.1002/1521-4141(200102)31:2<490::AID-IMMU490>3.0.CO
[9]  
2-H
[10]   Intracellular IL-1 Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-κB pathways [J].
Garat, C ;
Arend, WP .
CYTOKINE, 2003, 23 (1-2) :31-40